AU2001285232A1 - Alpha-difluoromethylornithine (dfmo) use in the human prostate - Google Patents

Alpha-difluoromethylornithine (dfmo) use in the human prostate

Info

Publication number
AU2001285232A1
AU2001285232A1 AU2001285232A AU8523201A AU2001285232A1 AU 2001285232 A1 AU2001285232 A1 AU 2001285232A1 AU 2001285232 A AU2001285232 A AU 2001285232A AU 8523201 A AU8523201 A AU 8523201A AU 2001285232 A1 AU2001285232 A1 AU 2001285232A1
Authority
AU
Australia
Prior art keywords
dfmo
difluoromethylornithine
alpha
human prostate
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285232A
Inventor
Eugene W. Gerner
Frank L. Meyskens Jr
Anne R. Simoneau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of Arizona
Original Assignee
University of California
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of Arizona filed Critical University of California
Publication of AU2001285232A1 publication Critical patent/AU2001285232A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
    • G11B7/12—Heads, e.g. forming of the optical beam spot or modulation of the optical beam
    • G11B7/22—Apparatus or processes for the manufacture of optical heads, e.g. assembly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Head (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Moving Of The Head For Recording And Reproducing By Optical Means (AREA)
  • Optical Recording Or Reproduction (AREA)
AU2001285232A 2000-08-24 2001-08-23 Alpha-difluoromethylornithine (dfmo) use in the human prostate Abandoned AU2001285232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22771400P 2000-08-24 2000-08-24
US60/227,714 2000-08-24
PCT/US2001/026332 WO2002015895A2 (en) 2000-08-24 2001-08-23 Alpha-difluoromethylornithine (dfmo) use in the human prostate

Publications (1)

Publication Number Publication Date
AU2001285232A1 true AU2001285232A1 (en) 2002-03-04

Family

ID=22854168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285232A Abandoned AU2001285232A1 (en) 2000-08-24 2001-08-23 Alpha-difluoromethylornithine (dfmo) use in the human prostate

Country Status (5)

Country Link
US (3) US20020137797A1 (en)
EP (1) EP1351675A2 (en)
JP (1) JP2004506683A (en)
AU (1) AU2001285232A1 (en)
WO (1) WO2002015895A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351675A2 (en) * 2000-08-24 2003-10-15 The Regents of the University of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
US7273888B2 (en) * 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
RU2005130636A (en) * 2003-03-04 2006-05-10 Уайт (Us) COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF ASTHMA OR OTHER ALLERGIC OR INFLAMMATORY DISEASES
CA2503554A1 (en) * 2004-04-27 2005-10-27 Proethic Laboratories, Llc Dietary supplement
US9072778B2 (en) * 2005-12-20 2015-07-07 University Of Hawaii Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
MX2008013917A (en) * 2006-05-03 2008-11-12 Wisconsin Alumni Res Found Nl, n4-bis (buta-i, 3-dienyl) butane-i, 4-diamine pharmaceutical compositions and uses thereof.
US9063122B2 (en) * 2008-10-17 2015-06-23 Alfredo Gallegos Biomodulators for treatment or prevention of disease
EP2430452B1 (en) 2009-05-14 2014-06-25 Arizona Board of Regents on Behalf of University of Arizona Carcinoma diagnosis and treatments, based on odc1 genotype
US20130217743A1 (en) * 2010-05-14 2013-08-22 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
FR2980709B1 (en) 2011-09-29 2013-10-25 Nutrialys Medical Nutrition Sa COMPOSITIONS CONTAINING SPERMINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
FR2985427B1 (en) 2012-01-10 2016-07-15 Nutrialys Medical Nutrition Sa COMPOSITIONS CONTAINING AGMATIN AND THEIR USES IN THE PREPARATION OF DRUGS OR NUTRACEUTICAL SUBSTANCES
DK2912193T3 (en) 2012-10-29 2018-12-03 Arizona Board Of Regents On Behalf Of Univ Of Arizona PREDICTIVE MARKERS FOR POLYAMINE INHIBITOR CANCER THERAPIES
US10655183B2 (en) 2014-06-18 2020-05-19 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on ODC1 genotype
MX2018005350A (en) 2015-10-30 2018-08-14 Cancer Prevention Pharmaceuticals Inc Eflornithine and sulindac, fixed dose combination formulation.
WO2017136533A1 (en) * 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
TW202110431A (en) 2019-05-17 2021-03-16 美商癌症預防製藥股份有限公司 Methods for treating familial adenomatous polyposis
WO2023039245A1 (en) * 2021-09-10 2023-03-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Biomarkers for nonalcoholic steatohepatitis and treatments thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413141A (en) * 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US5614557A (en) * 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4330559A (en) * 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) * 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) * 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) * 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
DE59307395D1 (en) * 1992-07-08 1997-10-23 Dianorm G Maierhofer Gmbh LIPOSOMEN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF A MEDICINAL PRODUCT
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO1998019667A1 (en) * 1996-11-01 1998-05-14 Ilex Oncology, Inc. Sustained release formulation containing dfmo
AU5526898A (en) * 1996-12-13 1998-07-03 Ilex Oncology, Inc. Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
AU9128998A (en) * 1997-09-04 1999-03-22 Richardson Labs, Inc. Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
CA2325080A1 (en) * 1998-03-28 1999-10-07 The Regents Of The University Of California Dfmo and sulindac combination in cancer chemoprevention
KR100370187B1 (en) * 1998-08-05 2003-03-17 삼성전자 주식회사 Optical recording/reproducing apparatus, tilt adjusting method therefor, and recording control method therefor
EP1351675A2 (en) * 2000-08-24 2003-10-15 The Regents of the University of California Alpha-difluoromethylornithine (dfmo) use in the human prostate

Also Published As

Publication number Publication date
US20040160876A1 (en) 2004-08-19
JP2004506683A (en) 2004-03-04
US20020137797A1 (en) 2002-09-26
EP1351675A2 (en) 2003-10-15
WO2002015895A2 (en) 2002-02-28
US6831286B2 (en) 2004-12-14
US20040162353A1 (en) 2004-08-19
WO2002015895A3 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2001287299A1 (en) Benzoylpyrazols and their use as herbicides
AU2001285232A1 (en) Alpha-difluoromethylornithine (dfmo) use in the human prostate
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU8420301A (en) Use
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
GB0101035D0 (en) Formulation and use thereof
GB0025788D0 (en) Use
AU7458201A (en) Laminate and use thereof
AU2001261750A1 (en) Laminate and its use
AU2002225749A1 (en) Powered periotome
AU2002227925A1 (en) Human beta-defensin-3
AU5464901A (en) Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides
AU2001232332A1 (en) Leptin-resistance ameliorating agents
AU2000231564A1 (en) Phosphororganic compounds and the use thereof
AUPQ526100A0 (en) Improvements in single use syringes
AU4432001A (en) Trityl-type compounds and their use
AU2001241875A1 (en) Human dynamin 40322
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
GB0005070D0 (en) Use
AU2001257100A1 (en) Nalpha, nomega-dialkyl aminomethylenephosphonic acids and use thereof
AU2002230539A1 (en) Alkylthio- and aryl(heteroyl)thio-substituted p-phenylenediamines, their manufacture and their use in rubber
AU2002219846A1 (en) Novel use
AU6286101A (en) New use